7R7R

Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol)

Summary for 7R7R

Entry DOI	10.2210/pdb7r7r/pdb
Descriptor	ALK tyrosine kinase receptor, (2R)-2-[5-(6-amino-5-{(1R)-1-[2-(1,3-dihydro-2H-1,2,3-triazol-2-yl)-5-fluorophenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol (3 entities in total)
Functional Keywords	kinase, transferase
Biological source	Homo sapiens (Human)
Total number of polymer chains	1
Total formula weight	37381.89
Authors	McTigue, M. (deposition date: 2021-06-25, release date: 2022-06-29, Last modification date: 2023-10-18)
Primary citation	Shiba-Ishii, A.,Johnson, T.W.,Dagogo-Jack, I.,Mino-Kenudson, M.,Johnson, T.R.,Wei, P.,Weinrich, S.L.,McTigue, M.A.,Walcott, M.A.,Nguyen-Phuong, L.,Dionne, K.,Acker, A.,Kiedrowski, L.A.,Do, A.,Peterson, J.L.,Barth, J.L.,Yeap, B.Y.,Gainor, J.F.,Lin, J.J.,Yoda, S.,Hata, A.N. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer, 3:710-722, 2022 Cited by PubMed: 35726063 DOI: 10.1038/s43018-022-00399-6 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.935 Å)

Structure validation